Are you interested in establishing an
International Clinical Trial (ICT) to high quality standards and on time? Or just a multicenter clinical study with a
large number of participants? And you probably don't want to overpay for it? Give us just a little of your time and we will tell you about a new interesting solution.
In 2017,
281 Authorizations to conduct International Multicenter Clinical Trials have been issued in Russia, which equals 40% of all authorizations issued during this period. In Belarus and Kazakhstan, the number is even smaller.
Ongoing studies are, of course, more numerous. But they are still dramatically less numerous than in the
European Union, the United States of America or, say, India. This is particularly surprising, i.e. the overall population of the Eurasian Economic Union (EAEU) (including Russia, Belarus and Kazakhstan, Armenia and Kyrgyzstan) sums up to
more than 185 million people. Why is it the way it is?
The main obstacle may be insufficient quality and guarantees of many research projects in the countries. And this opinion is not without reason.
There are often concerns about work of investigation sites (research centers), project teams, regulatory authorities and specialists in medical writing, epidemiology and biostatistics. Of course, these are successfully solved by international Contract Research Organizations. But
is your company ready to bear highest costs of International CROs' services?
On the other hand, there are
local companies, that conduct ICTs in Russia and Kazakhstan. But
can you always be confident in the quality of their work? Can you rely on them
meeting the deadlines?